All In Biotech

Drug Trial Radar · NCT07472491

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

A Prospective, Multicenter Phase 2/3 Study to Assess the Efficacy and Safety of Mangaciclanol in Adult Patients With Known or Highly Suspected Lesions Referred for Contrast-Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) or Body (LUMINA)

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 640 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

640

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts: * Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with known or highly suspected lesions of the CNS. The aim of the Phase 2 part is to identify an optimized dose of mangaciclanol for the Phase 3 part of the study. * Phase 3: Prospective, multicenter, randomized, controlled, single-blind, cross-over, including participants with known or highly suspected lesions of the CNS or body. The aim of the Phase 3 part is to further evaluate the efficacy and safety of mangaciclanol-enhanced MRI for the detection and characterization of lesions of the CNS or body. The investigational medicinal products (IMPs) used during the trial are mangaciclanol and gadobutrol (comparator IMP). Primary and key secondary efficacy analyses will be based on independent central blinded image evaluation (BIE), and Phase 2 data will be analyzed prior to commencement of Phase 3.

Conditions

  • Known or Highly Suspected Central Nervous System (CNS) Lesion
  • Known or Highly Suspected Body (Excluding CNS) Lesion

Interventions

  • Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mLDrug

    Single intravenous (IV) administration of Mangaciclanol (GEH200486 Injection, 0.5 mmol/mL) followed by a 20mL saline flush

  • MRI ScanDiagnostic test

    MRI Scan starting prior to IMP administration and continuing for up to 60 minutes post IMP administration

  • GadobutrolDrug

    Single intravenous (IV) administration of Gadobutrol (0.1 mmol/kg) followed by a 20mL saline flush

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2 Primary Endpoint - Overall diagnostic preferenceTime frame: 4-47 days
  2. Phase 3 Primary Endpoint - Lesion visualization criteriaTime frame: 4-74 days

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Renovatio Clinical

    The Woodlands, Texas · Recruiting

  • LTD Israel-Georgian Medical Research Clinic Healthycore

    Tbilisi, Georgia · Recruiting

  • LTD New Hospitals

    Tbilisi, Georgia · Recruiting

  • LLC Todua Clinic

    Tbilisi, Georgia · Recruiting

  • Arensia Exploratory Medicine - Moldova - IMSP Spitalul Clinic Republican Timofei Mosneaga

    Chisinau, Moldova · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.